Skip to main content

Eculizumab Dosage

Medically reviewed by Drugs.com. Last updated on May 24, 2024.

Applies to the following strengths: 10 mg/mL

Usual Adult Dose for Paroxysmal Nocturnal Hemoglobinuria

600 mg IV every week for 4 weeks, followed by 900 mg IV at week 5, then 900 mg IV every 2 weeks

Comments:


Use: For paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis

Usual Adult Dose for Hemolytic Uremic Syndrome

900 mg IV every week for the first 4 weeks, followed by 1200 mg IV at week 5, then 1200 mg IV every 2 weeks

Comments:


Use: For atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy

Usual Adult Dose for Myasthenia Gravis

900 mg IV every week for the first 4 weeks, followed by 1200 mg IV at week 5, then 1200 mg IV every 2 weeks

Comments:


Use: For patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive

Usual Adult Dose for Neuritis

900 mg IV every week for the first 4 weeks, followed by 1200 mg IV at week 5, then 1200 mg IV every 2 weeks

Comments:


Use: For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive

Usual Pediatric Dose for Hemolytic Uremic Syndrome

2 months and older:


Comments:

Use: For atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Data not available

Dose Adjustments

Dose Adjustment in Case of Plasmapheresis, Plasma Exchange, or Fresh Frozen Plasma Infusion: For adult and pediatric patients with aHUS and adult patients with gMG or MNOSD, supplemental dosing is required in the setting of concomitant plasmapheresis or plasma exchange, or fresh frozen plasma infusion (PE/PI):
SUPPLEMENTAL DOSING FOR PATIENTS RECEIVING PLASMAPHERESIS OR PLASMA EXCHANGE:

SUPPLEMENTAL DOSING FOR PATIENTS RECEIVING FRESH FROZEN PLASMA INFUSION (PI):

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for eculizumab. It includes elements to assure safe use. For additional information: http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm

US BOXED WARNINGS:
SERIOUS MENINGOCOCCAL INFECTIONS:


CONTRAINDICATIONS:


Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

General:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.